Recent studies in preclinical models of NB have also shown that 11q loss confers sensitivity to PARP inhibitors (130, 131), further supporting the hypothesis that heterozygous loss of ATM and other DDR genes determines sensitivity to PARP inhibition. The gene discussed is PARP1; the disease is neuroblastoma.